Higher percentages of CD16+ CD56+ , CD14+ , and CD11b+ , and lower percentages of CD3+ and CD19+ cells were obtained within PBMCs of cancer patients when compared to healthy individuals (Fig. S1B). This evidence concerns the gene NCAM1 and cancer.